Key result
Higher visit-to-visit LDL-C variability linked to ~2% greater risk of major events.
Why the study?
It was unknown whether visit-to-visit LDL-C variability can be reduced by moderate-intensity statin plus ezetimibe combination or by a treat-to-target strategy, and how these strategies relate to CV outcomes.
Does moderate-intensity statin plus ezetimibe or a treat-to-target strategy affect LDL-C variability and cardiovascular outcomes compared to high-intensity statin therapy in patients with atherosclerotic disease?
RCT (n=6,800)
randomized
Does moderate-intensity statin plus ezetimibe or a treat-to-target strategy affect LDL-C variability and cardiovascular outcomes compared to high-intensity statin therapy in patients with atherosclerotic disease?
Increased visit-to-visit LDL-C variability predicts adverse cardiovascular outcomes and is higher with a treat-to-target strategy compared to high-intensity statin therapy.
Answers are grounded in this paper and cite their sources.
MIS plus ezetimibe or TTS may match HIS for LDL-C stability; extends options beyond high-intensity regimens in practice and trials.
Background: Prior studies have shown an independent association between visit-to-visit variability in low-density lipoprotein cholesterol (LDL-C) and adverse cardiovascular (CV) events and that this variability can be reduced by high-intensity statins (HIS). However, it is not known whether LDL-C variability can be reduced by moderate-intensity statin (MIS) plus ezetimibe combination or by a treat-to-target strategy (TTS). Hypothesis: We aimed to evaluate whether visit-to-visit variability in LDL-C is affected by lipid-lowering strategies and its association with CV outcomes in patients treated with HIS or MIS plus ezetimibe or statins with a target LDL-C levels of 50 to 70 mg/dL (TTS). Methods: Data from the RACING and LODESTAR trial in patients with atherosclerotic disease, LDL-C variability was evaluated from 3 months after randomization. In the RACING trial, MIS plus ezetimibe combination therapy was compared with HIS monotherapy. In the LODESTAR trial, TTS with a target LDL-C level of 50 to 70 mg/dL by titration of the statin intensity was compared with HIS strategy. LDL-C variability was compared according to these lipid-lowering strategies. The primary endpoint was a composite of death, myocardial infarction, stroke, or coronary revascularization. Results: Among the 6800 patients included, when compared with patients randomized to HIS, LDL-C variability was similar in the group randomized to MIS plus ezetimibe combination (SD 8.92±7.15 vs 9.17±7.34, P=0.325) but higher in those randomized to TTS (SD 8.9±7.2 vs 10.6±7.7, P=0.001). There was a linear association between LDL-C variability and primary endpoint (Figure 1). The variability in LDL-C (by SD) was a predictor of primary endpoint (HR 1.024; 95% CI 1.014 to 1.035; P<0.001) even after adjustment for lipid-lowering strategy and mean LDL-C. Conclusions: Compared with HIS therapy, visit-to-visit variability in LDL-C was not increased in the MIS plus ezetimibe combination therapy, but was increased in the TTS. Even in those treated with MIS plus ezetimibe or HIS or statins with a target LDL-C levels of 50 to 70 mg/dL, increased LDL-C variability was significantly associated with higher risk of adverse CV outcome.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) conducted an RCT in atherosclerotic disease (n=6,800). Moderate-intensity statin plus ezetimibe or treat-to-target strategy vs. High-intensity statins was evaluated on composite of death, myocardial infarction, stroke, or coronary revascularization (HR 1.024, 95% CI 1.014 to 1.035, p=<0.001). Increased visit-to-visit LDL-C variability was associated with a higher risk of death, myocardial infarction, stroke, or coronary revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: